


# Curriculum Vitae

<b>Name</b>	<b>Sook Ryun Park</b>	
<b>Current Position &amp; Affiliation</b>	<b>Professor Asan Medical Center, University of Ulsan College of Medicine</b>	
<b>Country</b>	<b>Republic of Korea</b>	

## Educational Background

Ph.D., Internal Medicine, Seoul National University, Seoul, Korea, 2009  
 M.M., Internal Medicine, Seoul National University, Seoul, Korea, 2002  
 M.D., Internal Medicine, Seoul National University, Seoul, Korea, 1998

## Professional Experience

**Secretary General, Korean Society of Medical Oncology (2020-current)**  
**Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (2021-current)**  
**Associate Editor, JCO Clinical Cancer Informatics (2021-current)**  
**Associate Editor, Current Problems in Cancer (2020-current)**

Associate Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (2015-2021)  
 Clinical Assistant Professor, Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (2013-2015)  
 Senior Scientist, Division of Translational & Clinical Research I, Research Institute & Hospital, National Cancer Center (2009-2013)  
 Associate Scientist, Division of Translational & Clinical Research I, Research Institute & Hospital, National Cancer Center (2007-2009)  
 Staff Physician, Center for Gastric Cancer, Research Institute & Hospital, National Cancer Center (2005-2013)  
 Visiting Fellow, National Cancer Institute/National Institutes of Health, Bethesda, MD, USA (2010-2012)  
 Fellowship in Medical Oncology, Center for Gastric Cancer, Research Institute & Hospital, National Cancer Center (2004-2005)  
 Fellowship in Hematology/Oncology, Seoul National University Hospital, Seoul, Korea (2003-2004)

## Professional Organizations

2020-2021 International Conference of Korean Society of Medical Oncology, Secretary General

2021-2024 Korean National Cancer Control, Sub-Committee Member

2018-2020 Korean Society of Medical Oncology, Scientific Committee Member

2017-2018 Korean Cancer Association, International Committee Member

2017-2018 Korean Society of Medical Oncology, Planning Committee Member

2016-2018 Korean Cancer Association, Planning Committee Member

2014-2016 Korean Society of Medical Oncology, Publication Committee Member

2014-2016 Korean Association of Clinical Oncology, Judging Committee Member

2012-2016 Korean Cancer Study Group, External Cooperation Committee Member

## Main Scientific Publications

Yoo C, Kim JH, Ryu MH, **Park SR**, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, Tai D, Chan SL, Ryoo BY. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. *Liver Cancer* 2021;10(2):107-114.

Kim JH, Ahn B, Hong SM, Jung HY, Kim DH, Choi KD, Ahn JY, Lee JH, Na HK, Kim JH, Kim YH, Kim HR, Lee HJ, Kim SB, **Park SR\***. Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Cancer Res Treat.* 2021 Jun 23. (Online ahead of print)

Kummar S, Srivastava AK, Navas T, Cecchi F, Lee YH, Bottaro DP, **Park SR**, Do KT, Jeong W, Johnson BC, Voth AR, Rubinstein L, Wright JJ, Parchment RE, Doroshow JH, Chen AP. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors. *Invest New Drugs.* 2021 Jun 28. (Online ahead of print).

Jeong H, Im HS, Bang Y, Kim YH, Kim HR, Lee HJ, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Na HK, Ryu JS, Kang J, Kim SB, Kim JH, **Park SR\***. Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma. *Cancer Med.* 2021 Mar;10(5):1745-1758.

Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy. Kim EJ, Im HS, Lee J, Cho EH, Kim YH, Kim HR, Kim JH, **Park SR\***. *Curr Probl Cancer* 202;45(3):100685.

Lee KW, Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, Lee KH, Han HS, Seo BG, Jo JC, Lee HR, Kim JW, **Park SR**, Cho SH, Kang YK; SOPP study investigators. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of

advanced gastric cancer (SOPP trial). *Gastric Cancer* 2021;24(1):156-167.

A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). **Park SR**, Yoon DH, Kim JH, Kim YH, Kim HR, Lee HJ, Jung HY, Lee GH, Song HJ, Kim DH, Choi KD, Lee JH, Ahn JY, Ryu JS, Cho KJ, Kim SB. *Anticancer Res* 2019;39(9):5123-5133.

Oh CR, Kong SY, Im HS, Kim HJ, Kim MK, Yoon KA, Cho EH, Jang JH, Lee J, Kang J, **Park SR\***, Ryoo BY\*. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib. *BMC Cancer* 2019;19(1):292.

Park KS, Hong YS, Choi J, Yoon S, Kang J, Kim D, Lee KP, Im HS, Lee CH, Seo S, Kim SW, Lee DH, **Park SR\***. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. *BMB Rep* 2018;51(12):660-665.

Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, **Park SR**, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. *Ann Oncol.* 2018;29(5):1220-1226.

Kim HS, Ryu MH, Zang DY, **Park SR**, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. *Gastric Cancer.* 2018;21(5):802-810.

Kim MJ, Kong SY, Nam BH, Kim S, Park YI, **Park SR\***. A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results. *Pharmacogenet Genomics.* 2018;28(1):23-30.

Kim SY, Yoon MJ, Park YI, Kim MJ, Nam BH, **Park SR\***. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment. *Gastric Cancer.* 2018;21(3):453-463.

---